News & Updates

START-FIT, a prospective, single-arm, phase II trial, has found sequential transarterial chemoembolization (TACE) and stereotactic body radiotherapy (SBRT) followed by anti–PD-L1 treatment with avelumab to be a promising strategy for making patients with locally advanced unresectable hepatocellular carcinoma (HCC) amenable to curative treatment.

Circulating homocysteine and folate concentrations appear to play a significant role in the development of nonalcoholic fatty liver disease (NAFLD), a study has shown.

In patients with intermediate or advanced hepatocellular carcinoma (HCC), combining transarterial chemoembolization (TACE) with apatinib led to improvement in progression-free survival (PFS), according to a recent study from China.

Weekly bepirovirsen treatment may help reduce HBsAg* and hepatitis B virus (HBV) DNA levels in patients with chronic HBV infection, the phase IIb B-Clear study showed.

Patients who have recently been diagnosed with liver cirrhosis see a sharp increase in the risk of developing depression, a recent study has found.